Evidence map›Paper›PMID 34113737›Full record

ArticleAmerican journal of ophthalmology case reports2021

Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.

Connie M Sears, Yao Wang, Lucy A Bailey, Roger Turbin, Prem S Subramanian, Raymond Douglas, Kimberly Cockerham, Andrea L Kossler

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Dysthyroid optic neuropathy: emerging treatment strategies.Journal of endocrinological investigation · 2023
    Review
  14. Graves' orbitopathy post-SARS-CoV-2 vaccines: report on six patients.Journal of endocrinological investigation · 2023
    Article
  15. Thyroid Eye Disease.Life (Basel, Switzerland) · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2022
    Article
  20. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Connie M SearsDepartment of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Yao WangPrivate Practice, Beverly Hills, CA, USA.
Lucy A BaileyCentral Valley Eye Medical Group; Stockton, CA, USA.
Roger TurbinInstitute of Ophthalmology and Visual Science, Department of Ophthalmology, Rutgers New Jersey Medical School, Newark, NJ, USA.
Prem S SubramanianDepartment of Ophthalmology, University of Colorado School of Medicine and Sue Anschutz-Rodgers UC Health Eye Center, Aurora, CO, USA.
Raymond DouglasPrivate Practice, Beverly Hills, CA, USA.
Kimberly CockerhamDepartment of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Andrea L KosslerDepartment of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Beverly Hills Cancer Center · USNorth Valley Eye Medical Group · USStanford University · USRutgers New Jersey Medical SchoolUniversity of Colorado Anschutz Medical Campus · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

purposeTo study post-interventional findings in patients with dysthyroid optic neuropathy (DON) treated with teprotumumab. OBSERVATIONS: In this multicenter observational Case series CONCLUSIONS AND IMPORTANCE: Teprotumumab infusions resulted in medical decompression and objective resolution or improvement of dysthyroid optic neuropathy. Most patients had rapid improvement of visual acuity and reversal of RAPD. Post-infusion imaging demonstrated reduction in extraocular muscle size that correlated with improvement in visual dysfunction. However, patients who presented with longstanding severe visual loss had limited improvement. There was no recurrence of DON after completion of teprotumumab in our cohort.

Indexed as

Apical crowdingCompressive optic neuropathy (CON)Dysthyroid optic neuropathy (DON)Insulin-like growth factor I receptor (IGF-IR)Medical decompressionOptic atrophyOptic disc edemaRelative afferent pupillary defect (RAPD)TeprotumumabThyroid eye disease (TED)

Identifiers

PMID34113737
PMCPMC8170359
OpenAlexW3163188857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.